Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Return on Capital Employed (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Return on Capital Employed for 13 consecutive years, with 0.5% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed fell 1.0% year-over-year to 0.5%, compared with a TTM value of 0.5% through Dec 2025, down 1.0%, and an annual FY2025 reading of 0.43%, up 5.0% over the prior year.
  • Return on Capital Employed was 0.5% for Q4 2025 at Fate Therapeutics, up from 0.53% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.17% in Q2 2021 and bottomed at 0.54% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.39%, with a median of 0.42% recorded in 2023.
  • The sharpest move saw Return on Capital Employed increased 21bps in 2021, then dropped -27bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.25% in 2021, then plummeted by -102bps to 0.5% in 2022, then rose by 22bps to 0.39% in 2023, then decreased by -25bps to 0.49% in 2024, then fell by -2bps to 0.5% in 2025.
  • Business Quant data shows Return on Capital Employed for FATE at 0.5% in Q4 2025, 0.53% in Q3 2025, and 0.54% in Q2 2025.